270
Participants
Start Date
September 26, 2013
Primary Completion Date
January 8, 2016
Study Completion Date
January 8, 2016
ranibizumab
One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
Novartis Investigative Site, Marseille
Novartis Investigative Site, Caen
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Saint-Jean
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Montpellier
Novartis Investigative Site, Tours
Novartis Investigative Site, Tours
Novartis Investigative Site, Grenoble
Novartis Investigative Site, Grenoble
Novartis Investigative Site, Saint-Priest-en-Jarez
Novartis Investigative Site, Nantes
Novartis Investigative Site, Saitnt Herblain
Novartis Investigative Site, Angers
Novartis Investigative Site, Vannes
Novartis Investigative Site, Lille
Novartis Investigative Site, Strasbourg
Novartis Investigative Site, Mulhouse
Novartis Investigative Site, Écully
Novartis Investigative Site, Lyon
Novartis Investigative Site, Lyon
Novartis Investigative Site, Paris
Novartis Investigative Site, Paris
Novartis Investigative Site, Paris
Novartis Investigative Site, Paris
Novartis Investigative Site, Paris
Novartis Investigative Site, Paris
Novartis Investigative Site, Rouen
Novartis Investigative Site, Melun
Novartis Investigative Site, Mantes-la-Jolie
Novartis Investigative Site, Amiens
Novartis Investigative Site, Montauban
Novartis Investigative Site, Poitiers
Novartis Investigative Site, Bobigny
Novartis Investigative Site, Créteil
Novartis Investigative Site, Marseille
Novartis Investigative Site, Nice
Novartis Investigative Site, Paris
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY